Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4333

Website: zentalis.com

Address:

10275 Science Center Dr., Suite 200, San Diego, United States

zawojak Aug. 7 at 5:41 PM

$ZNTL dead until 1H of 2027. No wonder why dumped.

0 · Reply

lucabrix Aug. 7 at 2:51 PM

$ZNTL Wow what a BUY opportunity!!!

0 · Reply

Lukey63 Aug. 7 at 2:38 PM

$ZNTL Gross over-reaction on little real volume. This seems to be on schedule.

0 · Reply

Harlyboy Aug. 6 at 8:38 PM

$ZNTL wow phase 2 read out now 1h 2027, that sucks

0 · Reply

lucabrix Aug. 5 at 7:34 PM

$ZNTL YES!!!

1 · Reply

TraTDraHuKa Aug. 1 at 8:49 AM

$ZNTL initial target near $6.15 (average analyst target), with a secondary target pushing toward the 52-week high at $6.95n

0 · Reply

MadStockAlerts1 Aug. 1 at 8:05 AM

$ZNTL nothing but time

0 · Reply

MadStockAlerts1 Aug. 1 at 8:05 AM

$ZNTL just waiting…

0 · Reply

Gaben Jul. 28 at 2:30 PM

$ZNTL

0 · Reply

Broview Jul. 28 at 7:40 AM

$ZNTL ten bags if not bankrupt? Let us treat it as option trade?

0 · Reply

Zentalis price target raised to $5 from $4 at Morgan Stanley

Aug 6, 2026, 4:05 PM EDT - 4 days ago

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Aug 6, 2026, 7:00 AM EDT - 4 days ago

Zentalis Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 days ago

Zentalis Pharmaceuticals Earnings release: Q2 2026

Aug 3, 2026, 5:00 PM EDT - 7 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2026, 8:00 AM EDT - 9 days ago

Zentalis Pharmaceuticals Slides: Corporate presentation

2026-07-23T11:40:44.000Z - 18 days ago

Zentalis initiated with a Buy at Rodman & Renshaw

Jul 17, 2026, 4:15 PM EDT - 24 days ago

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

2026-07-17T08:40:25.000Z - 24 days ago

Zentalis initiated with an Outperform at Mizuho

2026-06-15T11:42:32.000Z - 2 months ago

Zentalis assumed with an Outperform at Oppenheimer

Jun 3, 2026, 3:45 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 2 months ago

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

May 26, 2026, 10:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:39 PM EDT - 2 months ago

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

May 20, 2026, 4:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 2:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 3 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 3 months ago

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

May 5, 2026, 8:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 1, 2026, 5:30 PM EDT - 3 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 10:27 AM EDT - 3 months ago

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

2026-04-17T19:20:16.000Z - 4 months ago

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Apr 17, 2026, 3:15 PM EDT - 4 months ago

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

2026-04-10T11:01:05.000Z - 4 months ago

Zentalis price target raised to $10 from $6 at Guggenheim

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Zentalis Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Zentalis Pharmaceuticals Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 5 months ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 9, 2026, 1:00 PM EDT - 5 months ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 5 months ago

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 12:40 PM EST - 5 months ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 3:30 PM EST - 6 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 4:05 PM EST - 6 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Jan 9, 2026, 6:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

2026-01-06T13:05:12.000Z - 7 months ago

Zentalis provides update, key milestones in 2025, expectations for 2026

Jan 6, 2026, 8:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Nov 12, 2025, 8:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:30 PM EST - 9 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T15:05:50.000Z - 9 months ago

Zentalis price target lowered to $4 from $8 at Morgan Stanley

Nov 10, 2025, 4:05 PM EST - 9 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Zentalis Pharmaceuticals Slides: Corporate Presentation

Oct 13, 2025, 4:05 PM EDT - 10 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-24T19:40:20.000Z - 11 months ago

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Sep 9, 2025, 7:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:15 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-26T20:10:19.000Z - 1 year ago

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

2025-08-07T10:27:10.000Z - 1 year ago

Zentalis price target lowered to $5 from $6 at Wells Fargo

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q2 2025

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: Jefferies Global Life Sciences Conference

May 27, 2025, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 23, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

May 20, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

2025-05-15T13:07:58.000Z - 1 year ago

Zentalis price target lowered to $9 from $10 at Oppenheimer

May 14, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

2025-04-28T12:11:44.000Z - 1 year ago

Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

2025-03-26T20:25:24.000Z - 1 year ago

Zentalis files $250M mixed securities shelf

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q4 2024

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Annual report: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Registration statement: Registration Filing

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: FY 2025

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Press release: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: Study Update

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 12, 2024, 9:30 AM EST - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q3 2024

Oct 7, 2024, 2:03 PM EDT - 2 years ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 7:00 AM EDT - 2 years ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

zawojak Aug. 7 at 5:41 PM

$ZNTL dead until 1H of 2027. No wonder why dumped.

0 · Reply

lucabrix Aug. 7 at 2:51 PM

$ZNTL Wow what a BUY opportunity!!!

0 · Reply

Lukey63 Aug. 7 at 2:38 PM

$ZNTL Gross over-reaction on little real volume. This seems to be on schedule.

0 · Reply

Harlyboy Aug. 6 at 8:38 PM

$ZNTL wow phase 2 read out now 1h 2027, that sucks

0 · Reply

lucabrix Aug. 5 at 7:34 PM

$ZNTL YES!!!

1 · Reply

TraTDraHuKa Aug. 1 at 8:49 AM

$ZNTL initial target near $6.15 (average analyst target), with a secondary target pushing toward the 52-week high at $6.95n

0 · Reply

MadStockAlerts1 Aug. 1 at 8:05 AM

$ZNTL nothing but time

0 · Reply

MadStockAlerts1 Aug. 1 at 8:05 AM

$ZNTL just waiting…

0 · Reply

Gaben Jul. 28 at 2:30 PM

$ZNTL

0 · Reply

Broview Jul. 28 at 7:40 AM

$ZNTL ten bags if not bankrupt? Let us treat it as option trade?

0 · Reply

BioTuesdays Jul. 23 at 4:25 PM

Rodman & Renshaw initiated coverage of Zentalis Pharmaceuticals $ZNTL with a “buy” rating and price target of $11.00. The stock closed at $4.50 on July 22. https://biotuesdays.com/2026/07/23/rodman-renshaw-starts-zentalis-at-buy-pt-11/

0 · Reply

lucabrix Jul. 23 at 3:03 PM

$ZNTL Rodman & Renshaw say BUY with 11$ TP

1 · Reply

STACKD0E Jul. 21 at 4:46 PM

$ZNTL WE DID IT!! 🙃✨️

1 · Reply

lucabrix Jul. 21 at 3:21 PM

$ZNTL Snackdaddy? ahahah

1 · Reply

StockScanners Jul. 21 at 3:22 AM

$ZNTL reached 5.58

0 · Reply

G101SPM Jul. 20 at 10:16 AM

$ZNTL $5.07 bid Holding long position at profit https://stocktwits.com/G101SPM/message/616485213 FACT: Zentalis® Pharmaceuticals, Inc. (ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

0 · Reply

sehrishaltaf95 Jul. 20 at 6:47 AM

$ZNTL moving slowly and steadily but nicely on daily chart with key support zone at 4. - 4.25. Next key level to test 5.75 - 6. Currently at 5.15

0 · Reply

SadyK189 Jul. 19 at 10:56 PM

Top Stocks to watch next week $BIYA $BXBL $SDOT $LEDS $ZNTL BIYA: Getting up on 4hours chart. Key support at 4.2 - 4.60. Next key level to test 6.3 - 6.7. Currently at 5.52 LEDS: Initially alerted at 2.14. Currently at 2.89. Looking good on daily chart. Key support zone at 2.05 - 2.25. Next key level to test 3.5 - 3.8. FGMC: Good close of hours candle. Key support zone at 9.8 - 10.40. Next key level to test 14.75 - 15.10. Currently at 13.7 SDOT: Getting up on 4hours chart. key support zone at 17.40 - 18.15. Next key level to test 28.8 - 29.75. Currently at 24.35 ZNTL moving slowly and steadily but nicely on daily chart with key support zone at 4.1 - 4.35. Next key level to test 5.85 - 6.15. Currently at 5.15

1 · Reply

ETAlpha Jul. 19 at 9:55 PM

Riding $SKYQ for weeks!$ZNTL runs from $4.35 floor to $10 PT! Weekend close ($SKYQ $3.80,$ZNTL $5.11). Futes look interesting.$ZNTL $4.35 support holding strong for a right-side squeeze to $10.

0 · Reply

StockScanners Jul. 18 at 8:25 AM

$ZNTL keep watch if this holds above 4.83

0 · Reply

stockpicker63 Jul. 18 at 4:50 AM

🚀 Weekly Results (July 13–17) Strong performance again this week. ⭐ Top Trades: $ZNTL +10.1% $CNMD +9.1% $DINO +8.8% $TRVI +8.7% $ANGO +7.4% 📊 Consistent gains across the board. Discipline. Strategy. Results.

0 · Reply

focafoca99 Jul. 17 at 8:53 PM

$ZNTL Featuring DENALI overall survival data on azenosertib at ESMO in October.

1 · Reply

Market Cap	300.41M
Revenue (ttm)	0.00
Net Income (ttm)	-137.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	824,700
Avg Vol	1,209,034
Day's Range	N/A - N/A
Shares Out	71.19M
Stochastic %K	12%
Beta	1.92
Analysts	Sell
Price Target	$7.30